BACKGROUND: Treprostinil, a prostacyclin analogue, is effective for the treatment of pulmonary arterial hypertension. However, information is scarce regarding treprostinil for treatment of chronic thromboembolic pulmonary hypertension (CTEPH). The aim of this study was to examine the efficacy and safety of subcutaneous treprostinil in this setting. METHODS: In this 24-week, randomised, double-blind controlled trial, we enrolled patients with CTEPH, classified as non-operable, or with persistent or recurrent pulmonary hypertension after pulmonary endarterectomy, in six European expert centres in Austria, Czech Republic, Germany, and Poland. Patients in WHO functional class III or IV with a 6-min walk distance of 150-400 m were randomly assigned at a 1:1 allocation ratio to continuous high-dose subcutaneous treprostinil (target dose around 30 ng/kg per min at week 12) or low-dose subcutaneous treprostinil (target dose around 3 ng/kg per min at week 12). The primary endpoint was the change from baseline in 6-min walk distance at week 24. All patients who received at least one dose of the study drug were included in the intention-to-treat efficacy and safety analyses based on assessment of adverse events. The trial was registered at ClinicalTrialsRegister.eu EudraCT number 2008-006441-10 and ClinicalTrials.gov, number NCT01416636. FINDINGS: From March 9, 2009, to June 9, 2016, 105 patients were enrolled with 53 (50%) patients randomly assigned to high-dose and 52 (50%) patients to low-dose subcutaneous treprostinil. At week 24, marginal mean 6-min walk distance improved by 44·98 m (95% CI 27·52 to 62·45) in the high-dose group, and by 4·29 m (95% CI -13·34 to 21·92) in the low-dose group (treatment effect 40·69 m, 95% CI 15·86 to 65·53, p=0·0016). 12 serious adverse events were reported in ten (19%) of 52 patients from the low-dose group and 16 serious adverse events were reported in nine (17%) of 53 patients from the high-dose group. The most common treatment-related adverse events in both groups were infusion site pain and other infusion site reactions. INTERPRETATION: Treatment with subcutaneous treprostinil was safe, and improved exercise capacity in patients with severe CTEPH. Subcutaneous treprostinil provides a parenteral treatment option for patients of WHO functional class III or IV and those who do not tolerate other therapies or need combination treatment. FUNDING: SciPharm Sàrl.

Clinical Department of Cardiology and Angiology of the 2nd Department of Medicine General University Hospital Prague Czech Republic

Department of Cardiac and Vascular Diseases Jagiellonian University Medical College Centre for Rare Cardiovascular Diseases John Paul 2 Hospital Krakow Poland

Department of Cardiology and Angiology of Medical Faculty Slovak Medical University and National Institute of Cardiovascular Diseases Bratislava Slovakia

Department of Cardiothoracic Surgery Medical University of Vienna Vienna Austria

Department of Internal Medicine 1 University Hospital Carl Gustav Carus Technische Universität Dresden Dresden Germany

Department of Internal Medicine 2 Division of Cardiology Medical University of Vienna Vienna Austria

Department of Internal Medicine 2 Ordensklinikum Linz Elisabethinen Linz Austria

Department of Pulmonary Circulation and Thromboembolic Diseases European Health Center Otwock Poland

Department of Pulmonary Diseases and Allergy Ljubljana University Medical Centre Ljubljana Slovenia

Department of Pulmonary Diseases Klinički Bolnički Centar Zagreb Zagreb Croatia

Department of Pulmonology Semmelweis University Budapest Hungary

000      

00000naa a2200000 a 4500

001      

bmc20022874

003      

CZ-PrNML

005      

20201214124923.0

007      

ta

008      

201125s2019 xxk f 000 0|eng||

009      

AR

024    7_

$a 10.1016/S2213-2600(18)30367-9 $2 doi

035    __

$a (PubMed)30477763

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a xxk

100    1_

$a Sadushi-Kolici, Roela $u Department of Internal Medicine II, Division of Cardiology, Medical University of Vienna, Vienna, Austria.

245    10

$a Subcutaneous treprostinil for the treatment of severe non-operable chronic thromboembolic pulmonary hypertension (CTREPH): a double-blind, phase 3, randomised controlled trial / $c R. Sadushi-Kolici, P. Jansa, G. Kopec, A. Torbicki, N. Skoro-Sajer, IA. Campean, M. Halank, I. Simkova, K. Karlocai, R. Steringer-Mascherbauer, M. Samarzija, B. Salobir, W. Klepetko, J. Lindner, IM. Lang,

520    9_

$a BACKGROUND: Treprostinil, a prostacyclin analogue, is effective for the treatment of pulmonary arterial hypertension. However, information is scarce regarding treprostinil for treatment of chronic thromboembolic pulmonary hypertension (CTEPH). The aim of this study was to examine the efficacy and safety of subcutaneous treprostinil in this setting. METHODS: In this 24-week, randomised, double-blind controlled trial, we enrolled patients with CTEPH, classified as non-operable, or with persistent or recurrent pulmonary hypertension after pulmonary endarterectomy, in six European expert centres in Austria, Czech Republic, Germany, and Poland. Patients in WHO functional class III or IV with a 6-min walk distance of 150-400 m were randomly assigned at a 1:1 allocation ratio to continuous high-dose subcutaneous treprostinil (target dose around 30 ng/kg per min at week 12) or low-dose subcutaneous treprostinil (target dose around 3 ng/kg per min at week 12). The primary endpoint was the change from baseline in 6-min walk distance at week 24. All patients who received at least one dose of the study drug were included in the intention-to-treat efficacy and safety analyses based on assessment of adverse events. The trial was registered at ClinicalTrialsRegister.eu EudraCT number 2008-006441-10 and ClinicalTrials.gov, number NCT01416636. FINDINGS: From March 9, 2009, to June 9, 2016, 105 patients were enrolled with 53 (50%) patients randomly assigned to high-dose and 52 (50%) patients to low-dose subcutaneous treprostinil. At week 24, marginal mean 6-min walk distance improved by 44·98 m (95% CI 27·52 to 62·45) in the high-dose group, and by 4·29 m (95% CI -13·34 to 21·92) in the low-dose group (treatment effect 40·69 m, 95% CI 15·86 to 65·53, p=0·0016). 12 serious adverse events were reported in ten (19%) of 52 patients from the low-dose group and 16 serious adverse events were reported in nine (17%) of 53 patients from the high-dose group. The most common treatment-related adverse events in both groups were infusion site pain and other infusion site reactions. INTERPRETATION: Treatment with subcutaneous treprostinil was safe, and improved exercise capacity in patients with severe CTEPH. Subcutaneous treprostinil provides a parenteral treatment option for patients of WHO functional class III or IV and those who do not tolerate other therapies or need combination treatment. FUNDING: SciPharm Sàrl.

650    _2

$a antihypertenziva $x aplikace a dávkování $x škodlivé účinky $7 D000959

650    _2

$a vztah mezi dávkou a účinkem léčiva $7 D004305

650    _2

$a dvojitá slepá metoda $7 D004311

650    _2

$a monitorování léčiv $x metody $7 D016903

650    _2

$a epoprostenol $x aplikace a dávkování $x škodlivé účinky $x analogy a deriváty $7 D011464

650    _2

$a tolerance zátěže $x účinky léků $7 D017079

650    _2

$a ženské pohlaví $7 D005260

650    _2

$a lidé $7 D006801

650    12

$a plicní hypertenze $x diagnóza $x farmakoterapie $x etiologie $x patofyziologie $7 D006976

650    _2

$a injekce subkutánní $7 D007279

650    _2

$a mužské pohlaví $7 D008297

650    _2

$a lidé středního věku $7 D008875

650    _2

$a plicní embolie $x komplikace $7 D011655

650    _2

$a stupeň závažnosti nemoci $7 D012720

650    _2

$a výsledek terapie $7 D016896

650    _2

$a test chůzí $x metody $7 D000070857

655    _2

$a klinické zkoušky, fáze III $7 D017428

655    _2

$a časopisecké články $7 D016428

655    _2

$a multicentrická studie $7 D016448

655    _2

$a randomizované kontrolované studie $7 D016449

655    _2

$a práce podpořená grantem $7 D013485

700    1_

$a Jansa, Pavel $u Clinical Department of Cardiology and Angiology of the 2nd Department of Medicine, General University Hospital, Prague, Czech Republic.

700    1_

$a Kopec, Grzegorz $u Department of Cardiac and Vascular Diseases, Jagiellonian University Medical College, Centre for Rare Cardiovascular Diseases, John Paul II Hospital, Krakow, Poland.

700    1_

$a Torbicki, Adam $u Department of Pulmonary Circulation and Thromboembolic Diseases, European Health Center, Otwock, Poland.

700    1_

$a Skoro-Sajer, Nika $u Department of Internal Medicine II, Division of Cardiology, Medical University of Vienna, Vienna, Austria.

700    1_

$a Campean, Ioana-Alexandra $u Department of Internal Medicine II, Division of Cardiology, Medical University of Vienna, Vienna, Austria.

700    1_

$a Halank, Michael $u Department of Internal Medicine I, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.

700    1_

$a Simkova, Iveta $u Department of Cardiology and Angiology of Medical Faculty, Slovak Medical University and National Institute of Cardiovascular Diseases, Bratislava, Slovakia.

700    1_

$a Karlocai, Kristof $u Department of Pulmonology, Semmelweis University, Budapest, Hungary.

700    1_

$a Steringer-Mascherbauer, Regina $u Department of Internal Medicine II, Ordensklinikum Linz Elisabethinen, Linz, Austria.

700    1_

$a Samarzija, Miroslav $u Department of Pulmonary Diseases, Klinički Bolnički Centar Zagreb, Zagreb, Croatia.

700    1_

$a Salobir, Barbara $u Department of Pulmonary Diseases and Allergy, Ljubljana University Medical Centre, Ljubljana, Slovenia.

700    1_

$a Klepetko, Walter $u Department of Cardiothoracic Surgery, Medical University of Vienna, Vienna, Austria.

700    1_

$a Lindner, Jaroslav $u Clinical Department of Cardiology and Angiology of the 2nd Department of Medicine, General University Hospital, Prague, Czech Republic.

700    1_

$a Lang, Irene M $u Department of Internal Medicine II, Division of Cardiology, Medical University of Vienna, Vienna, Austria. Electronic address: irene.lang@meduniwien.ac.at.

773    0_

$w MED00188827 $t The Lancet. Respiratory medicine $x 2213-2619 $g Roč. 7, č. 3 (2019), s. 239-248

856    41

$u https://pubmed.ncbi.nlm.nih.gov/30477763 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y a $z 0

990    __

$a 20201125 $b ABA008

991    __

$a 20201214124923 $b ABA008

999    __

$a ok $b bmc $g 1595193 $s 1113550

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2019 $b 7 $c 3 $d 239-248 $e 20181123 $i 2213-2619 $m The Lancet Respiratory medicine $n Lancet Respir Med $x MED00188827

LZP    __

$a Pubmed-20201125